Hypoxia is reported to participate in
tumor progression, promote drug resistance, and immune escape within tumor microenvironment, and thus impair
therapeutic effects including the
chemotherapy and advanced
immunotherapy. Here, a multifunctional biomimetic core-shell nanoplatform is reported for improving synergetic
chemotherapy and
immunotherapy. Based on the properties including good biodegradability and functionalities, the pH-sensitive zeolitic imidazolate framework 8 embedded with
catalase and
doxorubicin constructs the core and serves as an
oxygen generator and drug reservoir. Murine
melanoma cell membrane coating on the core provides
tumor targeting ability and elicits an immune response due to abundance of
antigens. It is demonstrated that this biomimetic core-shell nanoplatform with
oxygen generation can be partial to accumulate in
tumor and downregulate the expression of
hypoxia-inducible factor 1α, which can further enhance the
therapeutic effects of
chemotherapy and reduce the expression of
programmed death ligand 1 (PD-L1). Combined with immune checkpoints blockade
therapy by programmed death 1 (PD-1) antibody, the dual inhibition of the PD-1/PD-L1 axis elicits significant immune response and presents a robust effect in lengthening
tumor recurrent time and inhibiting
tumor metastasis. Consequently, the multifunctional nanoplatform provides a potential strategy of synergetic
chemotherapy and
immunotherapy.